{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:35:19Z","timestamp":1761514519455},"reference-count":45,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"Jazz and Novartis"},{"name":"Novartis, Celgene, CTI Biopharma and IOP Pharma"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.2217\/fon-2019-0612","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T14:17:12Z","timestamp":1579789032000},"page":"175-186","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Current and Future Role of Fedratinib in the Treatment of Myelofibrosis"],"prefix":"10.1080","volume":"16","author":[{"given":"Monica","family":"Ragheb","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy's & St. Thomas' NHS Foundation Trust,\rLondon,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire N","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's & St. Thomas' NHS Foundation Trust,\rLondon,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donal P","family":"McLornan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's & St. Thomas' NHS Foundation Trust,\rLondon,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.489"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3194-4"},{"key":"e_1_3_3_11_1","unstructured":"Celgene Corporation . U.S. FDA approves INREBIC\u00ae (Fedratinib) as first new treatment in nearly a decade for patients with myelofibrosis (2019). https:\/\/ir.celgene.com\/press-releases-archive\/press-release-details\/2019\/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis\/default.aspx"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.205"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep14538"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.775"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.255"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.015"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.56"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0862"},{"key":"e_1_3_3_20_1","unstructured":"INREBIC\u00ae [package insert] . Celgene Corporation NJ USA (2019). www.inrebicpro.com\/access-support"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03929-9"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.375"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.374"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4839.4839"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npv036"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058883"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.01.041"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14128"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0167-3"},{"issue":"1","key":"e_1_3_3_36_1","first-page":"4197","article-title":"Case series of potential wernicke's encephalopathy in patients treated with fedratinib","volume":"130","author":"Harrison CN","year":"2017","unstructured":"Harrison CN , MesaRA, Jamiesonet al.. Case series of potential wernicke's encephalopathy in patients treated with fedratinib. Blood130Suppl. 1, 4197 (2017). http:\/\/www.bloodjournal.org\/content\/130\/Suppl_1\/4197","journal-title":"Blood"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633404"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785790"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2758"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109799"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.323"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:01Z","timestamp":1719125161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.2217\/fon-2019-0612"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0612","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}